Phase Ib, Open Label, Combination Study of Nintedanib With 5-Azacitidine in Acute Myeloid Leukemia Characterized by HOX Gene Overexpression, That Are Not Candidates of Intensive Chemotherapy
Latest Information Update: 27 Dec 2023
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Nintedanib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 18 Dec 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2027.
- 18 Dec 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2025.
- 18 Dec 2023 Status changed from recruiting to active, no longer recruiting.